刘磊,李悦

• 1:哈尔滨医科大学附属第一医院心内五科

摘要(Abstract)：

<正>2012年1月,S Afr Med J杂志发表了由南非高血压协会制定的第五版南非高血压指南(以下简称"该指南")[1]。在南非,心血管疾病(cardiovascular disease,CVD)是第二位高致死因素,而高血压是导致CVD的主要病因之一。1998年南非高血压诊断标准为血压≥160/95 mm Hg或18岁以上正在服用降压药物者。按此标准统计,南非高血压患者

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘磊,李悦

参考文献(References)：

• [1]Bradshaw D,Groenewald P,Laubscher R,et al.Initial burdenof disease estimates for South Africa,2000[J].S Afr Med J,2003,93(9):682-688.
• [2]Steyn K,Gaziano T,Bradshaw D,et al.Hypertension in SouthAfrican adults:results from the Demographic and HealthReport 1998[J].J Hypertens,2001;19(3):1717-1725.
• [3]World Health Organization.CVD-Risk Management Packagefor Lowand Medium-Resource Settings.Geneva:WHO,2002.
• [4]Mancia G,Laurent S,Agahiti-Rosei E,et al.Reappraisal ofEuropean guidelines on hypertension management:a EuropeanSociety of Hypertension task force document[J].J Hypertens,2009,27(11):2121-2158.
• [5]Chobanian AV,Bakris GL,Black HR,et al.The seventh Reportof the Joint National Conference on Prevention,Detection,Evaluation and Treatment of High Blood Pressure:The JNC 7Report[J].JAMA 2003,289(19):2560-2572.
• [6]Mancia G,Laurent S,Agahiti-Rosei,et al.Reappraisal ofEuropean guidelines on hypertension management:a EuropeanSociety of Hypertension task force document[J].J Hypertens,2009,27(11):2121-2158.
• [7]Kaplan NM.Editorial.The choice or thiazide diuretics:why chlorthalidone may replace hydrochlorothiazide[J].Hypertension,2009,54(5):951-953.
• [8]Flack JM,Sica DA,Nesbitt S.Chlorthalidone versushydrochlorothiazide as the preferred diuretic.Is there a verdictyet?[J].Hypertension,2011,57(4):665-666.
• [9]DorschMP,GillespieBW,EricksonST,etal.Chlorthalidone reduced cardiovascular events comparedwith hydrochlorothiazide.A retrospective cohort analysis[J].Hypertension,2011,57(4):689-694.
• [10]Barnett AH,Bain SC,Bouter P,et al.Angiotensin receptorblockade versus converting-enzyme inhibition in Type2 diabetes and nephropathy[J].N Engl J Med,2004,351(19):1952-1961.
• [11]Dahl f B,Devereux RB,Kjeldsen SE,et al.Cardiovascularmorbidity and mortality in the Losartan Intervention forEndpoint reduction in hypertension study(LIFE):a randomizedtrial against atenolol[J].Lancet,2002,359(9311):995-1003.
• [12]Ruggenenti P,Fassi A,Ilieva AP,et al.Preventingmicroalbuminuria in type 2 diabetes[J].N Engl J Med,2004,351(19):1941-1951.
• [13]Schrader J,Lüders S,Kulschewski A,et al.Morbidity andmortality after stroke eprosartan compared compared withnitrendipine for secondary prevention:principal results of aprospective randomized controlled study(MOSES)[J].Stroke,2005,36(6):1218-1226.
• [14]ONTARGET Investigators,Yusuf S,Teo KK,et al.Telmisartan,ramipril,or both in patients at high risk for vascular events[J].N Engl J Med,2008,358(15):1547-1559.
• [15]McMurray JJV,Pitt B,Latini R,et al.Effects of the oral directrenin inhibitor aliskiren in patients with symptomatic heartfailure[J].Circ Heart Fail,2008,1(1):17-24.
• [16]Parving HH,Brenner BM,McMurray JJ,et al.Cardiorenalend points in a trial of aliskiren for type 2 diabetes[J].N Engl JMed,2012,367(23):2204-2213.
• [17]Gheorghiade M,B hm M,Greene SJ,et al.Effect of aliskirenon postdischarge mortality and heart failure readmissionsamong patients hospitalized for heart failure:the ASTRONAUTrandomized trial[J].JAMA,2013,309(11):1125-1135.
• [18]Kaplan W,Laing R.Fixed drug combinations as an innovativedelivery mechanism[M].Priority Medicines for Europe and theWorld.Geneva:World Health Organization,2004.
• [19]vanZwietenPA,FarsangC.Interactionsbetweenantihypertensive agents and other drugs[J].Blood Press,2003,12(5-6):351-352.
• [20]Egan A,Colman E.Weighing the benefits of high dosesimvastatin against the risk of myopathy[J].N Engl J Med,2011,365(4):285-287.
• [21]Lewis EJ,Hunsicker LG,Bain RP,Rohde RD.The effectof angiotensin-converting enzyme inhibition on diabeticnephropathy[J].N Engl J Med,1993,329(20):1456-1462.
• [22]Lewis EJ,Hunsicker LG,Clarke WR,et al.Renoprotectiveeffect of the angiotensin-receptor antagonist irbesartan inpatients with nephropathy due to type 2 diabetes[J].N Engl JMed,2001,345(12):851-860.
• [23]Ruggenenti P,Lauria G,Iliev IP,et al.Effects of mandipine anddelapril in hypertensive patients with type 2 diabetes mellitus:the delapril and mandipine for nephroprotection in diabetes(DEMAND)randomized clinical trial[J].Hypertension,2011,58(5):776-783.
• [24]Opie LH,Schall R.Old antihypertensives and new diabetes[J].J Hypertens,2004,22(8):1453-1458.
• [25]Opie LH,Seedat YK.Hypertension in sub-Saharan Africanpopulations[J].Circulation,2005,112(23):3562-3568.
• [26]Seedat YK.Diabetes mellitus in South African Indians[M].Type 2 Diabetes South Asians:epidemiology,risk factors andprevention,2007,40-44.
• [27]Seedat YK.Varying responses to hypotensive agents indifference racial groups,black versus white differences[J].JHypertens,1989,7(7):S15-S18.
• [28]Seaberg EC,Mu oz A,Lu M,et al.Association between highlyactive anti-retroviral therapy in a large cohort of men followedfrom 1984 to 2003[J].AIDS,2005,19(19):953-960.
• [29]Glesby MJ,Aberg JA,Kendall MA,et al.Pharmacokineticinteractions between indinavir plus ritonavir and calciumchannel blockers[J].Clin Pharmacol Ther,2005,78(2):143-153.
• [30]De Maat M,Ekhart GC,Huitema ADR,et al.Drug interactionsbetween antiretroviral drugs and comedicated agents[J].ClinPharmacokinet 2003,42(3):223-282.